У нас вы можете посмотреть бесплатно Annualized bleeding rates in patients with hemophilia A/B and inhibitors treated with concizumab или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Amy Shapiro, MD, Indiana University Hemophilia Center, Indianapolis, IN, presents the results of the Phase III explorer7 clinical trial (NCT04083781), which evaluated the efficacy of concizumab prophylaxis in patients with hemophilia A and B with inhibitors with or without target joints at baseline. Dr Shapiro highlights that concizumab prophylaxis was well-tolerated and significantly reduced annualized bleeding rates (ABR) at the 32-week cutoff, irrespective of the presence of target joints at baseline. This benefit was maintained at the 56-week time point. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.